Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2022-02-09 3:15 pm Purchase | 13G | AbbVie Inc. ABBV | VANGUARD GROUP INC | 146,312,069 8.28% | 3,748,995![]() (+2.63%) | View |
2022-02-03 4:29 pm Purchase | 13G | AbbVie Inc. ABBV | BlackRock Inc. BLK | 128,197,555 7.3% | 3,774,071![]() (+3.03%) | View |
2021-02-16 3:46 pm Sale | 13G | AbbVie Inc. ABBV | Capital Research Global Investors | 37,921,062 2.1% | -48,681,631![]() (-56.21%) | View |
2021-02-10 10:30 am Purchase | 13G | AbbVie Inc. ABBV | VANGUARD GROUP INC | 142,563,074 8.08% | 19,988,354![]() (+16.31%) | View |
2021-01-28 6:11 pm Purchase | 13G | AbbVie Inc. ABBV | BlackRock Inc. BLK | 124,423,484 7% | 25,829,674![]() (+26.20%) | View |
2020-02-14 12:03 pm Sale | 13G | AbbVie Inc. ABBV | Capital Research Global Investors | 86,602,693 5.8% | -8,258,634![]() (-8.71%) | View |
2020-02-12 09:23 am Purchase | 13G | AbbVie Inc. ABBV | VANGUARD GROUP INC | 122,574,720 8.28% | 1,991,295![]() (+1.65%) | View |
2020-02-05 11:38 am Purchase | 13G | AbbVie Inc. ABBV | BlackRock Inc. BLK | 98,593,810 6.7% | 2,804,911![]() (+2.93%) | View |
2019-11-08 12:14 pm Sale | 13G | AbbVie Inc. ABBV | Capital Research Global Investors | 94,861,327 6.4% | -78,706,916![]() (-45.35%) | View |
2019-02-14 07:27 am Purchase | 13G | AbbVie Inc. ABBV | VANGUARD GROUP INC | 120,583,425 8.01% | 730,863![]() (+0.61%) | View |
2019-02-13 6:11 pm Sale | 13G | AbbVie Inc. ABBV | Capital Research Global Investors | 173,568,243 11.5% | -19,442,530![]() (-10.07%) | View |
2019-02-11 07:46 am Sale | 13G | AbbVie Inc. ABBV | VANGUARD GROUP INC | 0 0% | -119,852,562![]() (Position Closed) | View |
2019-02-04 10:08 am Sale | 13G | AbbVie Inc. ABBV | BlackRock Inc. BLK | 95,788,899 6.4% | -5,533,302![]() (-5.46%) | View |
2018-02-13 6:38 pm Purchase | 13G | AbbVie Inc. ABBV | Capital Research Global Investors | 193,010,773 12% | 18,047,021![]() (+10.31%) | View |
2018-02-08 3:47 pm Purchase | 13G | AbbVie Inc. ABBV | VANGUARD GROUP INC | 119,852,562 7.5% | 10,315,799![]() (+9.42%) | View |
2018-02-08 09:48 am Purchase | 13G | AbbVie Inc. ABBV | BlackRock Inc. BLK | 101,322,201 6.3% | 8,903,634![]() (+9.63%) | View |